Cargando…
(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
BACKGROUND: The tau positron emission tomography (PET) ligand (18)F-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer’s disease (AD), but its utility in detecting tau aggregates in frontotemporal dementia (FTD) is uncertain. METHODS: We performed (18)F-flortaucipir imaging...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357510/ https://www.ncbi.nlm.nih.gov/pubmed/30704514 http://dx.doi.org/10.1186/s13195-019-0470-7 |
_version_ | 1783391812101079040 |
---|---|
author | Tsai, Richard M. Bejanin, Alexandre Lesman-Segev, Orit LaJoie, Renaud Visani, Adrienne Bourakova, Viktoriya O’Neil, James P. Janabi, Mustafa Baker, Suzanne Lee, Suzee E. Perry, David C. Bajorek, Lynn Karydas, Anna Spina, Salvatore Grinberg, Lea T. Seeley, William W. Ramos, Eliana M. Coppola, Giovanni Gorno-Tempini, Maria Luisa Miller, Bruce L. Rosen, Howard J. Jagust, William Boxer, Adam L. Rabinovici, Gil D. |
author_facet | Tsai, Richard M. Bejanin, Alexandre Lesman-Segev, Orit LaJoie, Renaud Visani, Adrienne Bourakova, Viktoriya O’Neil, James P. Janabi, Mustafa Baker, Suzanne Lee, Suzee E. Perry, David C. Bajorek, Lynn Karydas, Anna Spina, Salvatore Grinberg, Lea T. Seeley, William W. Ramos, Eliana M. Coppola, Giovanni Gorno-Tempini, Maria Luisa Miller, Bruce L. Rosen, Howard J. Jagust, William Boxer, Adam L. Rabinovici, Gil D. |
author_sort | Tsai, Richard M. |
collection | PubMed |
description | BACKGROUND: The tau positron emission tomography (PET) ligand (18)F-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer’s disease (AD), but its utility in detecting tau aggregates in frontotemporal dementia (FTD) is uncertain. METHODS: We performed (18)F-flortaucipir imaging in patients with the FTD syndromes (n = 45): nonfluent variant primary progressive aphasia (nfvPPA) (n = 11), corticobasal syndrome (CBS) (n = 10), behavioral variant frontotemporal dementia (bvFTD) (n = 10), semantic variant primary progressive aphasia (svPPA) (n = 2) and FTD associated pathogenic genetic mutations microtubule-associated protein tau (MAPT) (n = 6), chromosome 9 open reading frame 72 (C9ORF72) (n = 5), and progranulin (GRN) (n = 1). All patients underwent MRI and β-amyloid biomarker testing via (11)C-PiB or cerebrospinal fluid. (18)F-flortaucipir uptake in patients was compared to 53 β-amyloid negative normal controls using voxelwise and pre-specified region of interest approaches. RESULTS: On qualitative assessment, patients with nfvPPA showed elevated (18)F-flortacupir binding in the left greater than right inferior frontal gyrus. Patients with CBS showed elevated binding in frontal white matter, with higher cortical gray matter uptake in a subset of β-amyloid-positive patients. Five of ten patients with sporadic bvFTD demonstrated increased frontotemporal binding. MAPT mutation carriers had elevated (18)F-flortaucipir retention primarily, but not exclusively, in mutations with Alzheimer’s-like neurofibrillary tangles. However, tracer retention was also seen in patients with svPPA, and the mutations C9ORF72, GRN predicted to have TDP-43 pathology. Quantitative region-of-interest differences between patients and controls were seen only in inferior frontal gyrus in nfvPPA and left insula and bilateral temporal poles in MAPT carriers. No significant regional differences were found in CBS or sporadic bvFTD. Two patients underwent postmortem neuropathological examination. A patient with C9ORF72, TDP-43-type B pathology, and incidental co-pathology of scattered neurofibrillary tangles in the middle frontal, inferior temporal gyrus showed corresponding mild (18)F-flortaucipir retention without additional uptake matching the widespread TDP-43 type B pathology. A patient with sporadic bvFTD demonstrated punctate inferior temporal and hippocampus tracer retention, corresponding to the area of severe argyrophilic grain disease pathology. CONCLUSIONS: (18)F-flortaucipir in patients with FTD and predicted tauopathy or TDP-43 pathology demonstrated limited sensitivity and specificity. Further postmortem pathological confirmation and development of FTD tau-specific ligands are needed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13195-019-0470-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6357510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63575102019-02-07 (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes Tsai, Richard M. Bejanin, Alexandre Lesman-Segev, Orit LaJoie, Renaud Visani, Adrienne Bourakova, Viktoriya O’Neil, James P. Janabi, Mustafa Baker, Suzanne Lee, Suzee E. Perry, David C. Bajorek, Lynn Karydas, Anna Spina, Salvatore Grinberg, Lea T. Seeley, William W. Ramos, Eliana M. Coppola, Giovanni Gorno-Tempini, Maria Luisa Miller, Bruce L. Rosen, Howard J. Jagust, William Boxer, Adam L. Rabinovici, Gil D. Alzheimers Res Ther Research BACKGROUND: The tau positron emission tomography (PET) ligand (18)F-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer’s disease (AD), but its utility in detecting tau aggregates in frontotemporal dementia (FTD) is uncertain. METHODS: We performed (18)F-flortaucipir imaging in patients with the FTD syndromes (n = 45): nonfluent variant primary progressive aphasia (nfvPPA) (n = 11), corticobasal syndrome (CBS) (n = 10), behavioral variant frontotemporal dementia (bvFTD) (n = 10), semantic variant primary progressive aphasia (svPPA) (n = 2) and FTD associated pathogenic genetic mutations microtubule-associated protein tau (MAPT) (n = 6), chromosome 9 open reading frame 72 (C9ORF72) (n = 5), and progranulin (GRN) (n = 1). All patients underwent MRI and β-amyloid biomarker testing via (11)C-PiB or cerebrospinal fluid. (18)F-flortaucipir uptake in patients was compared to 53 β-amyloid negative normal controls using voxelwise and pre-specified region of interest approaches. RESULTS: On qualitative assessment, patients with nfvPPA showed elevated (18)F-flortacupir binding in the left greater than right inferior frontal gyrus. Patients with CBS showed elevated binding in frontal white matter, with higher cortical gray matter uptake in a subset of β-amyloid-positive patients. Five of ten patients with sporadic bvFTD demonstrated increased frontotemporal binding. MAPT mutation carriers had elevated (18)F-flortaucipir retention primarily, but not exclusively, in mutations with Alzheimer’s-like neurofibrillary tangles. However, tracer retention was also seen in patients with svPPA, and the mutations C9ORF72, GRN predicted to have TDP-43 pathology. Quantitative region-of-interest differences between patients and controls were seen only in inferior frontal gyrus in nfvPPA and left insula and bilateral temporal poles in MAPT carriers. No significant regional differences were found in CBS or sporadic bvFTD. Two patients underwent postmortem neuropathological examination. A patient with C9ORF72, TDP-43-type B pathology, and incidental co-pathology of scattered neurofibrillary tangles in the middle frontal, inferior temporal gyrus showed corresponding mild (18)F-flortaucipir retention without additional uptake matching the widespread TDP-43 type B pathology. A patient with sporadic bvFTD demonstrated punctate inferior temporal and hippocampus tracer retention, corresponding to the area of severe argyrophilic grain disease pathology. CONCLUSIONS: (18)F-flortaucipir in patients with FTD and predicted tauopathy or TDP-43 pathology demonstrated limited sensitivity and specificity. Further postmortem pathological confirmation and development of FTD tau-specific ligands are needed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13195-019-0470-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-31 /pmc/articles/PMC6357510/ /pubmed/30704514 http://dx.doi.org/10.1186/s13195-019-0470-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Tsai, Richard M. Bejanin, Alexandre Lesman-Segev, Orit LaJoie, Renaud Visani, Adrienne Bourakova, Viktoriya O’Neil, James P. Janabi, Mustafa Baker, Suzanne Lee, Suzee E. Perry, David C. Bajorek, Lynn Karydas, Anna Spina, Salvatore Grinberg, Lea T. Seeley, William W. Ramos, Eliana M. Coppola, Giovanni Gorno-Tempini, Maria Luisa Miller, Bruce L. Rosen, Howard J. Jagust, William Boxer, Adam L. Rabinovici, Gil D. (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
title | (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
title_full | (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
title_fullStr | (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
title_full_unstemmed | (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
title_short | (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
title_sort | (18)f-flortaucipir (av-1451) tau pet in frontotemporal dementia syndromes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357510/ https://www.ncbi.nlm.nih.gov/pubmed/30704514 http://dx.doi.org/10.1186/s13195-019-0470-7 |
work_keys_str_mv | AT tsairichardm 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT bejaninalexandre 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT lesmansegevorit 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT lajoierenaud 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT visaniadrienne 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT bourakovaviktoriya 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT oneiljamesp 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT janabimustafa 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT bakersuzanne 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT leesuzeee 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT perrydavidc 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT bajoreklynn 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT karydasanna 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT spinasalvatore 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT grinbergleat 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT seeleywilliamw 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT ramoselianam 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT coppolagiovanni 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT gornotempinimarialuisa 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT millerbrucel 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT rosenhowardj 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT jagustwilliam 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT boxeradaml 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes AT rabinovicigild 18fflortaucipirav1451taupetinfrontotemporaldementiasyndromes |